查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1379994

蛋白質工程市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按產品類型、技術、最終用戶和地區、競爭細分

Protein Engineering Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Product Type, Technology, End User, and By Region, Competition
出版日期: | 出版商: TechSci Research | 英文 189 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022 年，全球蛋白質工程市場價值為 25.6 億美元，預計到 2028 年，預測期內將出現令人印象深刻的成長，複合CAGR為11%。蛋白質工程是生物技術的一個分支，涉及精心設計、修改和最佳化蛋白質來創造新功能、改進現有功能或針對特定應用客製化它們。蛋白質是重要的生物大分子，在生物體中發揮廣泛的功能，包括催化化學反應（酵素）、運輸分子、提供結構支持和調節細胞過程。蛋白質工程利用對蛋白質結構和功能的理解來操縱這些分子以達到各種目的。分子生物學技術的進步使得合成和修飾編碼具有特定序列的蛋白質的基因成為可能。這使得研究人員能夠創造全新的蛋白質或修改現有的蛋白質以適應各種應用。

主要市場促進因素

市場概況
預測期 2024-2028
2022 年市場規模 25.6億美元
2028 年市場規模 47.6億美元
2023-2028 年CAGR 11.00%
成長最快的細分市場 疫苗
最大的市場 北美洲

技術進步

蛋白質工程的技術進步在塑造該領域並擴大其在各個行業（包括製藥、生物技術、農業和工業流程）的應用方面發揮了關鍵作用。成簇規則間隔短回文重複序列 (CRISPR) 和 CRISPR 相關蛋白 9 (Cas9) 技術徹底改變了蛋白質工程。它允許精確的基因組編輯，使得高特異性和高效地修改基因和工程蛋白質成為可能。這對藥物開發、農業和基礎研究有深遠的影響。定向進化是一種強大的技術，可以模仿自然選擇來最佳化蛋白質的特定功能。透過迭代的突變和選擇，研究人員可以設計具有增強特性的蛋白質，例如增加親和力、穩定性或酶活性。高通量篩選 (HTS) 方法變得更加複雜和自動化，能夠快速篩選大型蛋白質庫以獲得所需的特性。這加速了新型酵素、治療抗體和其他基於蛋白質的產品的發現。包括分子建模和機器學習在內的計算方法的進步使研究人員能夠預測工程蛋白質的結構和功能。這可以節省設計階段的時間和資源，並有助於理解蛋白質-配體相互作用。合成生物學技術能夠創造全新的蛋白質和生物系統。研究人員可以設計和合成編碼具有客製化功能的新型蛋白質的基因，從而擴大蛋白質工程的可能性。蛋白質表現系統（例如酵母、細菌和哺乳動物細胞）的改進增強了重組蛋白和治療抗體的產生。這些進步提高了工程蛋白質的產量和品質。

了解蛋白質折疊和穩定性對於蛋白質工程至關重要。計算工具和實驗技術改進了蛋白質結構和穩定性的預測，有助於設計更穩健的蛋白質。下一代定序（NGS）技術促進了遺傳變異和表現模式的分析，使研究人員能夠更有效地識別和表徵潛在的蛋白質工程標靶。無細胞蛋白質合成系統變得更有效率和通用。它們無需活細胞即可快速生產蛋白質，更容易設計和研究各種蛋白質。 CrispRGold 和 Prime Editing 等基因組編輯技術的最新發展為修改基因序列提供了更高的精度和控制。這些進步對基因治療和蛋白質工程有深遠的影響。 ChIP-seq 和蛋白質-DNA 交聯等技術使研究人員能夠在分子層面上研究蛋白質-DNA 相互作用。這對於理解基因調控和設計 DNA 結合蛋白至關重要。單細胞蛋白質體學技術的進步可以分析單一細胞的蛋白質含​​量，從而深入了解細胞異質性和疾病機制。這項因素將有助於全球蛋白質工程市場的發展。

不斷發展的生物技術和製藥行業

生物技術和製藥行業見證了向生物製劑的轉變，生物製劑是從活生物體中提取的藥物。這包括單株抗體、疫苗和其他基於蛋白質的療法。蛋白質工程在設計、最佳化和生產這些生物製品方面發揮著至關重要的作用，滿足了對更有針對性和更有效的治療日益成長的需求。發現和開發新藥的過程通常涉及與疾病相關的特定蛋白質的識別和修飾。蛋白質工程技術能夠修飾這些蛋白質，以增強其治療特性或創造全新的候選藥物。製藥業越來越傾向於個人化醫療，即根據患者的個人情況量身定做治療方案。蛋白質工程允許客製化治療蛋白質，以匹配個別患者的遺傳和分子特徵，從而改善治療結果。蛋白質工程在罕見疾病和孤兒疾病療法的開發中發揮了重要作用，這些疾病可能沒有大量的患者群體。製藥業對這些利基市場表現出了興趣，推動了對蛋白質工程服務和技術的需求。

生物製藥產業依靠生物製造流程來生產大量的蛋白質藥物。蛋白質工程有助於最佳化這些治療性蛋白質的表達、產量和穩定性，確保高效且經濟高效的生產。製藥公司不斷尋求透過創新和差異化產品來擴大其藥物管道。蛋白質工程可以開發新型生物製劑和以蛋白質為基礎的療法，幫助公司保持競爭力。聯合療法的開發，即使用多種藥物來針對疾病的不同方面，是製藥業的成長趨勢。蛋白質工程可用於設計協同作用的互補治療性蛋白質。隨著一些生物藥物的專利到期，生物相似藥的市場不斷成長，生物相似藥是現有生物製劑的高度相似版本。蛋白質工程用於製造具有可比較功效和安全性的生物相似藥。生技和製藥公司大力投資研發，將新藥推向市場。這項投資包括蛋白質工程研究和技術開發的資金。製藥公司、生物技術公司和學術機構在蛋白質工程研究方面的合作已變得普遍。這些合作夥伴關係推動創新並加速以蛋白質為基礎的療法的開發。 COVID-19 大流行等事件凸顯了快速開發疫苗和治療方法的必要性。蛋白質工程在 COVID-19 疫苗和治療方法的開發中發揮了關鍵作用，展示了其在應對全球健康挑戰方面的重要性。這項因素將加快全球蛋白質工程市場的需求。

更關注罕見疾病

罕見疾病，也稱為孤兒病，由於發病率低，往往缺乏有效的治療方法。蛋白質工程提供了一種有前途的方法來開發針對這些疾病的客製化療法，解決重大的未滿足的醫療需求。對罕見疾病的研究通常涉及識別這些疾病背後的特定基因突變或蛋白質異常。蛋白質工程允許客製化治療性蛋白質，以精確靶向罕見疾病所涉及的分子途徑，從而實現精準醫學方法。世界各地的政府和監管機構為治療罕見疾病的孤兒藥的開發提供激勵措施。蛋白質工程有助於設計和最佳化這些藥物，包括單株抗體和酵素替代療法。罕見疾病通常是由特定蛋白質異常引起的。蛋白質工程技術能夠開發出能夠糾正或補償這些異常的標靶療法，從而改善治療結果。

針對罕見疾病相關蛋白質而設計的單株抗體在治療某些形式的肌肉營養不良症和溶酶體貯積症等疾病方面顯示出巨大的前景。蛋白質工程與基因療法密切相關，基因療法在治療罕見遺傳性疾病方面具有巨大潛力。工程蛋白質，例如病毒載體或酶，可用於向罕見疾病患者傳遞治療基因。對於某些罕見的代謝性疾病，酵素替代療法至關重要。蛋白質工程技術可以最佳化這些治療酵素的穩定性、活性和標靶性。在監管激勵措施、資金增加和蛋白質工程技術進步的共同推動下，孤兒藥市場一直在穩步成長。這種成長鼓勵了對罕見疾病研發的投資。罕見疾病領域學術研究人員、製藥公司和患者權益團體之間的合作變得更加普遍。這種合作加速了基於蛋白質的療法的研究和開發。致力於罕見疾病的患者團體和基金會的大力宣傳努力提高了人們對研究和治療發展的認知和支持。這些努力推動了對蛋白質工程解決方案的資助和興趣。基因組學和蛋白​​質組學等診斷技術的進步使得罕見疾病特異性生物標記的鑑定成為可能。然後蛋白質工程可用於開發診斷和標靶治療。這項因素將加速全球蛋白質工程市場的需求。

主要市場挑戰

蛋白質設計的複雜性

蛋白質具有複雜的3D結構，這對其功能至關重要。設計具有正確折疊的特定結構的蛋白質是一項具有挑戰性的任務，因為氨基酸序列的微小變化可能導致錯誤折疊和功能喪失。預測設計蛋白質的確切功能可能具有挑戰性。許多蛋白質在生物系統中具有多方面的作用，設計蛋白質來執行特定功能可能非常複雜。確保設計的蛋白質穩定並正確折疊成其功能構像是一項重大挑戰。實現正確的蛋白質折疊對其活性和功效至關重要。蛋白質經常與其他分子相互作用，例如配體、輔因子或其他蛋白質。設計與特定分子選擇性且高親和力相互作用的蛋白質可能很複雜。設計參與特定蛋白質-蛋白質相互作用的蛋白質尤其具有挑戰性。預測不同蛋白質如何相互作用並準確地設計這些相互作用是很複雜的。蛋白質設計需要多個學科的專業知識，包括生物學、化學、生物資訊學和結構生物學。這些領域的專家之間的合作通常是必要的。

永續性和環境議題

蛋白質工程研究通常需要大量資源，包括實驗室設備、消耗品和能源。這些資源密集型流程對環境的影響可能值得關注。蛋白質產品的生產，如治療性蛋白質、酵素和替代蛋白質（如植物性和細胞性肉類），可能會對環境產生影響。最佳化生物製造流程以使其更具永續性是一項挑戰。用於各種應用（包括農業和工業生物技術）的基因改造生物（GMO）的開發引起了環境和監管方面的擔憂。確保基因改造生物的安全使用並解決潛在的生態影響至關重要。生物製造過程會產生廢棄物和副產品，可能對環境造成影響。管理和最大限度地減少廢物流是永續發展的挑戰。許多蛋白質工程過程需要受控的環境和精確的條件，這可能是能源密集的。減少能源消耗和轉向再生能源是永續發展的優先事項。在蛋白質工程中使用化學物質（例如用於 DNA 合成和蛋白質純化的試劑）可能會對環境產生影響。開發更綠色的化學方法是永續發展目標。雖然替代蛋白（植物蛋白和細胞蛋白）通常被認為比傳統畜牧業更具永續性，但它們的環境足跡可能會有所不同。減少這些技術對環境的影響是一項持續的挑戰。

主要市場趨勢

蛋白質工程的擴展

蛋白質工程用於修改作物的基因組成以增強特定性狀。這可以包括增強對病蟲害的抵抗力，提高對環境壓力（例如乾旱或鹽度）的耐受性，以及最佳化營養成分。透過蛋白質工程開發具有增強抗病性的作物，減少了對化學農藥的需求，有助於環境友善和永續農業。抗蟲工程作物可以保護產量並減少對化學殺蟲劑的依賴，對環境和農民都有好處。蛋白質工程可以幫助培育更能抵禦乾旱條件的作物，這對於面臨缺水和氣候變遷挑戰的地區至關重要。蛋白質工程透過提高維生素和礦物質等必需營養素的含量來提高作物的營養價值。透過提高作物產量和減少對化學投入的需求，蛋白質工程作物可以為更永續和環境友善的農業實踐做出貢獻。使用透過蛋白質工程設計的基因改造作物可能會減少土壤侵蝕，降低溫室氣體排放，減少農業徑流，從而減輕環境危害。生物強化涉及提高作物必需營養素的水平。蛋白質工程可以在主要作物的生物強化中發揮作用，以解決弱勢群體的營養不良和營養缺乏問題。

細分市場洞察

技術洞察

2022 年，全球蛋白質工程市場理性蛋白質設計領域佔據最大佔有率，預計未來幾年將繼續擴大。該技術在酵素工程和抗體開發方面的廣泛應用佔據了主導佔有率。酶工程的商業用途大幅增加，這導致了具有適當催化能力的改良和修飾酶的產生。定點誘變是理性設計工程方法中經常採用的方法，其高市場滲透率有助於推動該類別的發展。

產品類型見解

2022年，全球蛋白質工程市場單株抗體領域佔據最大的收入佔有率，預計未來幾年將繼續擴大。用於創造治療改進的單株抗體的研發支出不斷增加，是影響這些技術利用率提高的主要因素之一。由於擴大使用標靶單株抗體來治療癌症和其他慢性疾病，預計該細分市場很快就會成長。像這樣，採用尖端技術的遺傳平台的出現，例如用於實現有效蛋白質工程以開發單株抗體的下一代定序，預計將顯著提高成長潛力。

最終用途見解

2022 年，全球蛋白質工程市場製藥和生技公司細分市場佔據最大佔有率，預計未來幾年將繼續擴大。其中很大一部分是由於電腦模擬藥物研究模型在治療神經系統問題、癌症和糖尿病方面的廣泛使用的結果。這些企業不斷努力透過使用電腦建模來創建專利到期藥物的藥物版本來保持其市場地位。該領域也受到公共和商業醫療保健組織不斷增加的資金和財政支持的推動，這些資金和財政支持旨在創建複雜的蛋白質工程技術，從而改善患者的治療效果。

區域洞察

2022年，北美地區在全球蛋白質工程市場中佔據主導地位。該地區佔據的較大比例可能是由於主要市場參與者為提高研發能力而推動的合作數量不斷增加。高市佔率受到該地區重要公司的影響，包括安捷倫科技公司和賽默飛世爾科技公司。

預計亞太地區在預測期內將以最快的CAGR成長。因為亞洲發展中國家自體免疫疾病、心血管疾病和癌症疾病的發生率很高。此外，印度和中國等新興經濟體的高速經濟發展預計將支持該產業在該領域未開發前景的擴張。此外，預計該地區的擴張將得益於蛋白質工程應用研究和臨床測試的大量人口基礎。

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球蛋白質工程市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品類型（胰島素、單株抗體、凝血因子（血液因子 + 組織纖溶酶原）、疫苗、生長因子（荷爾蒙 + 細胞激素）和其他產品類型）
    • 按技術分類（非理性蛋白質設計和理性蛋白質設計）
    • 按最終用戶（製藥和生物技術公司、學術機構和合約研究組織 (CRO)）
    • 按地區
    • 按公司分類 (2022)
  • 市場地圖

第 6 章：亞太地區蛋白質工程市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品類型
    • 依技術
    • 按最終用戶
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國蛋白質工程
    • 印度蛋白質工程
    • 澳洲蛋白質工程
    • 日本蛋白質工程
    • 韓國蛋白質工程

第 7 章：歐洲蛋白質工程市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品類型
    • 依技術
    • 按最終用戶
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 西班牙
    • 義大利
    • 英國

第 8 章：北美蛋白質工程市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品類型
    • 依技術
    • 按最終用戶
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 9 章：南美洲蛋白質工程市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品類型
    • 依技術
    • 按最終用戶
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲蛋白質工程市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品類型
    • 依技術
    • 按最終用戶
    • 按國家/地區
  • MEA：國家分析
    • 南非蛋白質工程
    • 沙烏地阿拉伯蛋白質工程
    • 阿拉伯聯合大公國蛋白質工程

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 最近的發展
  • 產品發布
  • 併購

第 13 章：全球蛋白質工程市場：SWOT 分析

第 14 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第 15 章：大環境分析

第16章：競爭格局

  • 安捷倫科技公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 安進公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 布魯克公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • Bio-Rad 實驗室公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 禮來公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 默克公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 諾和諾德公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 珀金埃爾默公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 賽默飛世爾科技公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 沃特世公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 金斯瑞美國公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 通用電氣醫療集團
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis

第 17 章：策略建議

第 18 章：關於我們與免責聲明

簡介目錄
Product Code: 16973

Global Protein Engineering Market has valued at USD 2.56 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 11% through 2028. Protein engineering is a branch of biotechnology that involves the deliberate design, modification, and optimization of proteins to create new functions, improve existing ones, or tailor them for specific applications. Proteins are essential biological macromolecules that perform a wide range of functions in living organisms, including catalyzing chemical reactions (enzymes), transporting molecules, providing structural support, and regulating cellular processes. Protein engineering harnesses the understanding of protein structure and function to manipulate these molecules for various purposes. Advances in molecular biology techniques have made it possible to synthesize and modify genes encoding proteins with specific sequences. This allows researchers to create entirely new proteins or modify existing ones for various applications.

The growing demand for biopharmaceuticals, including monoclonal antibodies, vaccines, and other protein-based therapies, was a significant driver. Protein engineering techniques are essential for optimizing the production and efficacy of these drugs. Ongoing advancements in genomics, transcriptomics, and proteomics were providing valuable insights into the role of proteins in disease pathways. This knowledge fueled the demand for protein engineering techniques to develop targeted therapies. The biotechnology and pharmaceutical industries were experiencing sustained growth, with increased investment in research and development. This growth was driving the demand for protein engineering tools and services. Protein engineering was playing a crucial role in the development of therapies for rare and orphan diseases. The potential for high returns in this niche market was a driver for investment and innovation. Protein engineering was being used to design enzymes with enhanced properties for various industrial applications, including biofuel production, food processing, and waste management.

Key Market Drivers

Market Overview
Forecast Period2024-2028
Market Size 2022USD 2.56 Billion
Market Size 2028USD 4.76 Billion
CAGR 2023-202811.00%
Fastest Growing SegmentVaccines
Largest MarketNorth America

Technological Advancements

Technological advancements in protein engineering have played a pivotal role in shaping the field and expanding its applications in various industries, including pharmaceuticals, biotechnology, agriculture, and industrial processes. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and CRISPR-associated protein 9 (Cas9) technology revolutionized protein engineering. It allows precise genome editing, making it possible to modify genes and engineer proteins with high specificity and efficiency. This has far-reaching implications in drug development, agriculture, and basic research. Directed evolution is a powerful technique that mimics natural selection to optimize proteins for specific functions. Through iterative rounds of mutation and selection, researchers can engineer proteins with enhanced properties, such as increased affinity, stability, or enzymatic activity. High-Throughput Screening (HTS) methods have become more sophisticated and automated, enabling the rapid screening of large libraries of proteins for desired properties. This accelerates the discovery of novel enzymes, therapeutic antibodies, and other protein-based products. Advances in computational methods, including molecular modeling and machine learning, allow researchers to predict the structure and function of engineered proteins. This saves time and resources in the design phase and helps in understanding protein-ligand interactions. Synthetic biology techniques enable the creation of entirely new proteins and biological systems. Researchers can design and synthesize genes encoding novel proteins with tailored functions, expanding the possibilities for protein engineering. Improvements in protein expression systems, such as yeast, bacteria, and mammalian cells, have enhanced the production of recombinant proteins and therapeutic antibodies. These advancements increase the yield and quality of engineered proteins.

Understanding protein folding and stability is crucial for protein engineering. Computational tools and experimental techniques have improved the prediction of protein structures and stability, aiding in the design of more robust proteins. Next-Generation Sequencing (NGS) technologies have facilitated the analysis of genetic variation and expression patterns, allowing researchers to identify and characterize potential protein engineering targets more effectively. Cell-free protein synthesis systems have become more efficient and versatile. They enable the rapid production of proteins without the need for living cells, making it easier to engineer and study various proteins. Recent developments in genome editing technologies like CrispRGold and Prime Editing offer even greater precision and control in modifying genetic sequences. These advancements have far-reaching implications for gene therapy and protein engineering. Techniques such as ChIP-seq and protein-DNA cross-linking enable researchers to study protein-DNA interactions at the molecular level. This is critical for understanding gene regulation and designing DNA-binding proteins. Advancements in single-cell proteomics technologies allow the profiling of individual cells' protein content, providing insights into cellular heterogeneity and disease mechanisms. This factor will help in the development of the Global Protein Engineering Market.

Growing Biotechnology and Pharmaceutical Sectors

The biotechnology and pharmaceutical industries have witnessed a shift towards biologics, which are drugs derived from living organisms. This includes monoclonal antibodies, vaccines, and other protein-based therapeutics. Protein engineering plays a crucial role in designing, optimizing, and producing these biologics, meeting the increasing demand for more targeted and effective treatments. The process of discovering and developing new drugs often involves the identification and modification of specific proteins associated with diseases. Protein engineering techniques enable the modification of these proteins to enhance their therapeutic properties or to create entirely new drug candidates. The pharmaceutical sector is increasingly moving towards personalized medicine, where treatments are tailored to individual patient profiles. Protein engineering allows for the customization of therapeutic proteins to match the genetic and molecular characteristics of individual patients, improving treatment outcomes. Protein engineering has been instrumental in the development of therapies for rare and orphan diseases, which may not have large patient populations. The pharmaceutical industry has shown interest in these niche markets, driving demand for protein engineering services and technologies.

The biopharmaceutical industry relies on biomanufacturing processes to produce large quantities of protein-based drugs. Protein engineering helps optimize the expression, yield, and stability of these therapeutic proteins, ensuring efficient and cost-effective production. Pharmaceutical companies continuously seek to expand their drug pipelines with innovative and differentiated products. Protein engineering allows for the development of novel biologics and protein-based therapies, helping companies stay competitive. The development of combination therapies, where multiple drugs are used to target different aspects of a disease, is a growing trend in the pharmaceutical sector. Protein engineering can be employed to design complementary therapeutic proteins that work together synergistically. As patents for some biologic drugs expire, there is a growing market for biosimilars, which are highly similar versions of existing biologics. Protein engineering is used to create biosimilars with comparable efficacy and safety profiles. Biotechnology and pharmaceutical companies invest heavily in research and development to bring new drugs to market. This investment includes funding for protein engineering research and technology development. Collaboration between pharmaceutical companies, biotech firms, and academic institutions in protein engineering research has become common. These partnerships drive innovation and accelerate the development of protein-based therapies. Events like the COVID-19 pandemic have highlighted the need for rapid vaccine and therapeutic development. Protein engineering played a pivotal role in the development of COVID-19 vaccines and treatments, showcasing its importance in addressing global health challenges. This factor will pace up the demand of the Global Protein Engineering Market.

Increased Focus on Rare Diseases

Rare diseases, also known as orphan diseases, often lack effective treatments due to their low prevalence. Protein engineering offers a promising approach to develop tailored therapies for these diseases, addressing significant unmet medical needs. The study of rare diseases often involves identifying specific genetic mutations or protein abnormalities that underlie these conditions. Protein engineering allows for the customization of therapeutic proteins to precisely target the molecular pathways involved in rare diseases, enabling precision medicine approaches. Governments and regulatory agencies worldwide provide incentives for the development of orphan drugs to treat rare diseases. Protein engineering is instrumental in designing and optimizing these drugs, including monoclonal antibodies and enzyme replacement therapies. Rare diseases are often caused by specific protein abnormalities. Protein engineering techniques enable the development of targeted therapies that can correct or compensate for these abnormalities, leading to improved treatment outcomes.

Monoclonal antibodies engineered to target rare disease-related proteins have shown significant promise in treating conditions such as certain forms of muscular dystrophy and lysosomal storage disorders. Protein engineering is closely linked to gene therapy, which holds great potential for treating rare genetic disorders. Engineered proteins, such as viral vectors or enzymes, can be used to deliver therapeutic genes to patients with rare diseases. For certain rare metabolic disorders, enzyme replacement therapies are essential. Protein engineering techniques can optimize the stability, activity, and targeting of these therapeutic enzymes. The orphan drug market has been growing steadily, driven by a combination of regulatory incentives, increased funding, and advances in protein engineering technologies. This growth encourages investment in research and development for rare diseases. Collaboration between academic researchers, pharmaceutical companies, and patient advocacy groups in the field of rare diseases has become more common. Such collaborations accelerate research and the development of protein-based therapies. Strong advocacy efforts by patient groups and foundations dedicated to rare diseases have raised awareness and support for research and treatment development. These efforts drive funding and interest in protein engineering solutions. Advances in diagnostic technologies, such as genomics and proteomics, enable the identification of rare disease-specific biomarkers. Protein engineering can then be used to develop diagnostics and targeted therapies. This factor will accelerate the demand of the Global Protein Engineering Market.

Key Market Challenges

Complexity of Protein Design

Proteins have complex three-dimensional structures that are crucial for their functions. Designing proteins with specific structures that fold correctly is a challenging task, as small changes in amino acid sequences can lead to misfolding and loss of function.Predicting the exact function of a designed protein can be challenging. Many proteins have multifaceted roles within biological systems, and designing a protein to perform a specific function can be highly complex. Ensuring that a designed protein is stable and properly folds into its functional conformation is a significant challenge. Achieving the correct protein fold is crucial for its activity and efficacy. Proteins often interact with other molecules, such as ligands, cofactors, or other proteins. Designing a protein that interacts selectively and with high affinity with a particular molecule can be complex. Designing proteins that engage in specific protein-protein interactions can be particularly challenging. Predicting how different proteins will interact with one another and engineering those interactions accurately is complex. Protein design requires expertise in multiple disciplines, including biology, chemistry, bioinformatics, and structural biology. Collaborations among experts in these fields are often necessary.

Sustainability and Environmental Concerns

Protein engineering research often requires substantial resources, including laboratory equipment, consumables, and energy. The environmental impact of these resource-intensive processes can be a concern. The production of protein-based products, such as therapeutic proteins, enzymes, and alternative proteins (like plant-based and cell-based meats), can have environmental implications. Optimizing biomanufacturing processes to be more sustainable is a challenge. The development of genetically modified organisms (GMOs) for various applications, including agriculture and industrial biotechnology, raises environmental and regulatory concerns. Ensuring the safe use of GMOs and addressing potential ecological impacts is essential. Biomanufacturing processes can generate waste and byproducts that may have environmental consequences. Managing and minimizing waste streams is a sustainability challenge. Many protein engineering processes require controlled environments and precise conditions, which can be energy intensive. Reducing energy consumption and transitioning to renewable energy sources are priorities for sustainability. The use of chemicals in protein engineering, such as reagents for DNA synthesis and protein purification, can have environmental impacts. Developing greener chemistry approaches is a sustainability goal. While alternative proteins (plant-based and cell-based) are often considered more sustainable than traditional animal agriculture, their environmental footprint can vary. Reducing the environmental impact of these technologies is an ongoing challenge.

Key Market Trends

Expansion of Protein Engineering

Protein engineering is used to modify the genetic makeup of crops to enhance specific traits. This can include increasing resistance to pests and diseases, improving tolerance to environmental stressors (e.g., drought or salinity), and optimizing nutritional content. Developing crops with enhanced disease resistance through protein engineering reduces the need for chemical pesticides, contributing to environmentally friendly and sustainable agriculture. Engineering crops for pest resistance can protect yields and reduce the reliance on chemical insecticides, benefiting both the environment and farmers. Protein engineering can help create crops that are more resilient to drought conditions, which is critical in regions facing water scarcity and climate change challenges. Protein engineering is applied to increase the nutritional value of crops by enhancing the content of essential nutrients, such as vitamins and minerals. By improving crop yields and reducing the need for chemical inputs, protein-engineered crops can contribute to more sustainable and environmentally friendly agricultural practices. The use of genetically modified crops designed through protein engineering may lead to reduced soil erosion, lower greenhouse gas emissions, and decreased agricultural runoff, thus mitigating environmental harm. Biofortification involves increasing the levels of essential nutrients in crops. Protein engineering can play a role in biofortifying staple crops to address malnutrition and nutrient deficiencies in vulnerable populations.

Segmental Insights

Technology Insights

In 2022, the Global Protein Engineering Market rational protein design segment held the largest share and is predicted to continue expanding over the coming years. The technology's vast application in enzyme engineering and antibody development accounts for the dominant share. Enzyme engineering has seen a tremendous increase in its commercial uses, which has led to the creation of improved and modified enzymes with the appropriate catalytic capabilities. Site-directed mutagenesis is one method that is often employed in rational design engineering approaches, and its high market penetration helps to drive the category.

Product Type Insights

In 2022, the Global Protein Engineering Market monoclonal antibodies segment held the largest revenue share and is predicted to continue expanding over the coming years. The rising R&D expenditure for creating therapeutically improved monoclonal antibodies is one of the main factors influencing the increased utilisation of these technologies. Soon, the segment is anticipated to grow due to the rising use of targeted monoclonal antibodies for the treatment of cancer and other chronic diseases. Like this, the emergence of genetic platforms that employ cutting-edge technology, such as next-generation sequencing for enabling effective protein engineering for the development of monoclonal antibodies, is anticipated to significantly boost the growth potential.

End Use Insights

In 2022, the Global Protein Engineering Market pharmaceutical & biotechnology companies segment held the largest share and is predicted to continue expanding over the coming years. The significant portion is a result of the expanding usage of in silico drug research models for the treatment of neurological issues, cancer, and diabetes. These businesses constantly strive to preserve their market presence by using computer modelling to create drug versions of patent-expiring medications. The segment is also being driven by the increasing funding and financial support from public and commercial healthcare organisations for the creation of sophisticated protein engineering technologies that will improve patient outcomes.

Regional Insights

The North America region dominated the Global Protein Engineering Market in 2022. The bigger proportion that this region has grabbed is probably due to the increasing number of collaborations that major market participants have promoted for improving their R&D capabilities. The high market share has been influenced by the existence of important companies in the area, including Agilent Technologies and Thermo Fisher Scientific, Inc.

The Asia Pacific region is projected to grow at the fastest CAGR over the forecast period. Because developing Asian nations have high rates of autoimmune, cardiovascular, and cancer diseases. Additionally, the high economic development in emerging economies like India and China is anticipated to support the sector's expansion in this area's unexplored prospects. Additionally, it is projected that the region's expansion will be aided by the availability of a sizable population base for the research and clinical testing of protein engineering applications.

Key Market Players

  • Agilent Technologies Inc.
  • Amgen Inc.
  • Bruker Corporation
  • Bio-Rad Laboratories Inc.
  • Eli Lilly and Company
  • Merck KGaA
  • Novo Nordisk AS
  • PerkinElmer Inc.
  • Thermo Fisher Scientific Inc.
  • Waters Corporation
  • Genscripts USA, Inc.
  • GE Healthcare

Report Scope:

In this report, the Global Protein Engineering Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Protein Engineering Market, By Product Type:

  • Insulin
  • Monoclonal Antibodies
  • Coagulation Factors (Blood Factors + Tissue Plasminogen)
  • Vaccines
  • Growth Factors (Hormones + Cytokine)
  • Other Product Types

Protein Engineering Market, By Technology:

  • Irrational Protein Design
  • Rational Protein Design

Protein Engineering Market, By End User:

  • Pharmaceutical and Biotechnology Companies
  • Academic Institutions
  • Contract Research Organizations (CROs)

Global Protein Engineering Market, By region:

  • North America
  • United States
  • Canada
  • Mexico
  • Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Protein Engineering Market.

Available Customizations:

  • Global Protein Engineering Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Protein Engineering Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Insulin, Monoclonal Antibodies, Coagulation Factors (Blood Factors + Tissue Plasminogen), Vaccines, Growth Factors (Hormones + Cytokine), and Other Product Types)
    • 5.2.2. By Technology (Irrational Protein Design and Rational Protein Design)
    • 5.2.3. By End User (Pharmaceutical and Biotechnology Companies, Academic Institutions, and Contract Research Organizations (CROs))
    • 5.2.4. By Region
    • 5.2.5. By Company (2022)
  • 5.3. Market Map

6. Asia Pacific Protein Engineering Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Technology
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. Asia Pacific: Country Analysis
    • 6.3.1. China Protein Engineering Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Technology
        • 6.3.1.2.3. By End User
    • 6.3.2. India Protein Engineering Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Technology
        • 6.3.2.2.3. By End User
    • 6.3.3. Australia Protein Engineering Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Technology
        • 6.3.3.2.3. By End User
    • 6.3.4. Japan Protein Engineering Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Product Type
        • 6.3.4.2.2. By Technology
        • 6.3.4.2.3. By End User
    • 6.3.5. South Korea Protein Engineering Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Product Type
        • 6.3.5.2.2. By Technology
        • 6.3.5.2.3. By End User

7. Europe Protein Engineering Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Technology
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Protein Engineering Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By End User
    • 7.3.2. Germany Protein Engineering Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By End User
    • 7.3.3. Spain Protein Engineering Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By Type
    • 7.3.4. Italy Protein Engineering Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Technology
        • 7.3.4.2.3. By End User
    • 7.3.5. United Kingdom Protein Engineering Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Technology
        • 7.3.5.2.3. By End User

8. North America Protein Engineering Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Technology
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Protein Engineering Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By End User
    • 8.3.2. Mexico Protein Engineering Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By End User
    • 8.3.3. Canada Protein Engineering Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By End User

9. South America Protein Engineering Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Technology
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Protein Engineering Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By End User
    • 9.3.2. Argentina Protein Engineering Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By End User
    • 9.3.3. Colombia Protein Engineering Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By End User

10. Middle East and Africa Protein Engineering Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Technology
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Protein Engineering Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By End User
    • 10.3.2. Saudi Arabia Protein Engineering Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By End User
    • 10.3.3. UAE Protein Engineering Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Protein Engineering Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

  • 16.1. Agilent Technologies Inc.
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (In case of listed companies)
    • 16.1.5. Recent Developments
    • 16.1.6. SWOT Analysis
  • 16.2. Amgen Inc.
    • 16.2.1. Business Overview
    • 16.2.2. Company Snapshot
    • 16.2.3. Products & Services
    • 16.2.4. Financials (In case of listed companies)
    • 16.2.5. Recent Developments
    • 16.2.6. SWOT Analysis
  • 16.3. Bruker Corporation
    • 16.3.1. Business Overview
    • 16.3.2. Company Snapshot
    • 16.3.3. Products & Services
    • 16.3.4. Financials (In case of listed companies)
    • 16.3.5. Recent Developments
    • 16.3.6. SWOT Analysis
  • 16.4. Bio-Rad Laboratories Inc.
    • 16.4.1. Business Overview
    • 16.4.2. Company Snapshot
    • 16.4.3. Products & Services
    • 16.4.4. Financials (In case of listed companies)
    • 16.4.5. Recent Developments
    • 16.4.6. SWOT Analysis
  • 16.5. Eli Lilly and Company
    • 16.5.1. Business Overview
    • 16.5.2. Company Snapshot
    • 16.5.3. Products & Services
    • 16.5.4. Financials (In case of listed companies)
    • 16.5.5. Recent Developments
    • 16.5.6. SWOT Analysis
  • 16.6. Merck KGaA
    • 16.6.1. Business Overview
    • 16.6.2. Company Snapshot
    • 16.6.3. Products & Services
    • 16.6.4. Financials (In case of listed companies)
    • 16.6.5. Recent Developments
    • 16.6.6. SWOT Analysis
  • 16.7. Novo Nordisk AS
    • 16.7.1. Business Overview
    • 16.7.2. Company Snapshot
    • 16.7.3. Products & Services
    • 16.7.4. Financials (In case of listed companies)
    • 16.7.5. Recent Developments
    • 16.7.6. SWOT Analysis
  • 16.8. PerkinElmer Inc.
    • 16.8.1. Business Overview
    • 16.8.2. Company Snapshot
    • 16.8.3. Products & Services
    • 16.8.4. Financials (In case of listed companies)
    • 16.8.5. Recent Developments
    • 16.8.6. SWOT Analysis
  • 16.9. Thermo Fisher Scientific Inc.
    • 16.9.1. Business Overview
    • 16.9.2. Company Snapshot
    • 16.9.3. Products & Services
    • 16.9.4. Financials (In case of listed companies)
    • 16.9.5. Recent Developments
    • 16.9.6. SWOT Analysis
  • 16.10. Waters Corporation
    • 16.10.1. Business Overview
    • 16.10.2. Company Snapshot
    • 16.10.3. Products & Services
    • 16.10.4. Financials (In case of listed companies)
    • 16.10.5. Recent Developments
    • 16.10.6. SWOT Analysis
  • 16.11. Genscripts USA, Inc.
    • 16.11.1. Business Overview
    • 16.11.2. Company Snapshot
    • 16.11.3. Products & Services
    • 16.11.4. Financials (In case of listed companies)
    • 16.11.5. Recent Developments
    • 16.11.6. SWOT Analysis
  • 16.12. GE Healthcare
    • 16.12.1. Business Overview
    • 16.12.2. Company Snapshot
    • 16.12.3. Products & Services
    • 16.12.4. Financials (In case of listed companies)
    • 16.12.5. Recent Developments
    • 16.12.6. SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer